An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

C. Herold, Kevan; N. Bundy, Brian; Alice Long, S.; A. Bluestone, Jeffrey; A. DiMeglio, Linda; J. Dufort, Matthew; E. Gitelman, Stephen; A. Gottlieb, Peter; P. Krischer, Jeffrey; S. Linsley, Peter; B. Marks, Jennifer; D. Moore, Wayne; Moran, Antoinette; Rodriguez, Henry; E. Russell, William; Schatz, Desmond; S. Skyler, Jay; Tsalikian, Eva; K. Wherrett, Diane; Ziegler, Anette-Gabriele; J. Greenbaum, Carla

doi:10.1056/nejmoa1902226

Public

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

Published in New England Journal of Medicine • Jun 9, 2019

Authors:

Kevan C. Herold

Brian N. Bundy

S. Alice Long

Abstract

BACKGROUND: Type 1 diabetes is a chronic autoimmune disease that leads to destruction of insulin-producing beta cells and dependence on exogenous insulin for survival. Some interventions have delayed the loss of insulin production in patients with type 1 diabetes, but interventions that might affect...

Subject

Medicine

Diabetes mellitus

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!